Contact Us
Registered Address:
The Pharma Letter
Victoria House
26 Queen Victoria St
Reading
RG1 1TG
For trial and subscription enquiries please email subscriptions@thepharmaletter.com
For editorial enquiries, press releases and events please email newsdesk@thepharmaletter.com
For all other queries please email enquiries@thepharmaletter.com
Latest Features
Today's issue
Company Spotlight
A clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and broader neurodegenerative biology. Neurizon aims to advance its lead small-molecule candidate into pivotal clinical testing and position it for regulatory evaluation and eventual patient access.
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze